Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial

Arthritis and Rheumatism

Volumn 54, Issue 10, 2006, Pages 3310-3318

  Mazlumzadeh, Mehrdad ^a   Hunder, Gene G ^b   Easley, Kirk A ^c   Calamia, Kenneth T ^d   Matteson, Eric L ^b   Griffing, W Leroy ^a   Younge, Brian R ^b   Weyand, Cornelia M ^c   Goronzy, Jörg J ^c,e  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c EMORY UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; METHYLPREDNISOLONE; PREDNISONE; SODIUM CHLORIDE;

ABDOMINAL BLEEDING; ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASEPTIC NECROSIS; CARDIOVASCULAR DISEASE; CATARACT; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COMPRESSION FRACTURE; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ESOPHAGUS CANDIDIASIS; EYE DISEASE; FEMALE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GIANT CELL ARTERITIS; GLAUCOMA; GLUCOSE INTOLERANCE; HERPES ZOSTER; HIP FRACTURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; MALE; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; PELVIS FRACTURE; PEPTIC ULCER; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RELAPSE; REMISSION; SIDE EFFECT; SLEEP APNEA SYNDROME; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; RECURRENCE; REMISSION INDUCTION; TEMPORAL ARTERITIS; TREATMENT OUTCOME;

EID: 33750370542     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22163     Document Type: Article

References (31)

1. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;139:505-15.
2. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
3. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology 1993;100:550-5.
4. Calamia KT, Hunder GG. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum 1981;24:1414-8.
5. Evans JM, Bowles CA, Bjornsson J, Mullany CJ, Hunder GG. Thoracic aortic aneurysm and rupture in giant cell arteritis: a descriptive study of 41 cases. Arthritis Rheum 1994;37:1539-47.
6. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995;122:502-7.
7. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Maltesen EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003;48:3522-31.
8. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003;48:3532-7.
9. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8.
10. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997;40:1873-8.
11. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45:136-8.
12. Hernandez-Garcia C, Soriano C, Morado C, Ramos P, Fernandez-Gutierrez B, Herrero M, et al. Methotrexate treatment in the management of giant cell arteritis. Scand J Rheumatol 1994;23:295-8.
13. Schaufelberger C, Andersson R, Nordborg E. No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol 1998;37:464-5.
14. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al, for the International Network for the Study of Systemic Vasculitides (INSSYS). A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-18.
15. Nesher G, Sonnenblick M. Steroid-sparing medications in temporal arteritis-report of three cases and review of 174 reported patients. Clin Rheumatol 1994;13:289-92.
16. Evans JM, Batts KP, Hunder GG. Persistent giant cell arteritis despite corticosteroid treatment. Mayo Clin Proc 1994;69:1060-1.
17. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994;120:987-92.
18. Brack A, Rittner HL, Younge BR, Kaltschmidt C, Weyand CM, Goronzy JJ. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997;99:2842-50.
19. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
20. Sailler L, Carreiro M, Ollier S, Juchet H, Delobel P, Ferrand D, et al. Non-complicated Horton's disease: initial treatment with methylprednisolone 500 mg/day bolus for three days followed by 20 mg/day prednisone-equivalent. Evaluation of 15 patients. Rev Med Interne 2001;22:1032-8. In French.
21. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000;27:1484-91.
22. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun Rev 2004;3:46-53.
23. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349:160-9.
24. Krupa WM, Dewan M, Jeon MS, Kurtin PJ, Younge BR, Goronzy JJ, et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002;161:1815-23.
25. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004;199:173-83.
26. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis [review]. Arthritis Rheum 1999;42:844-53.
27. Rittner HL, Kaiser M, Brack A, Szweda LI, Goronzy JJ, Weyand CM. Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999;84:1050-8.
28. Rittner HL, Hafner V, Klimiuk PA, Szweda LI, Goronzy JJ, Weyand CM. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J Clin Invest 1999;103:1007-13.
29. Kaiser M, Younge B, Bjornsson J, Goronzy JJ, Weyand CM. Formation of new vasa vasorum in vasculitis: production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999;155:765-74.
30. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-94.
31. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041-8.